TDM-1 results reported @ ASCO annual mtg 2012 now in New England Journal of Medicine

[karen z]

Thanks so much for posting.
K

[Rolepaul]

Roche has been granted a priority review of its Herceptin successor, known as T-DM1. The action date for this review by the U.S. FDA is February 26th, 2013. A spokesperson for Roche has expressed their belief that this priority review increases the likelihood of a market release in early 2013.

This would hopefully mean that a lot more women would get treated. The company is very hopeful.